NRSN
Neurosense Therapeutics LtdNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage limited
$3.49+0.29%
Close Oct 13, 2026
- Market cap
- —
- 1 month
- -49.4%
- 3 months
- -75.7%
- 1 year
- -85.3%
- Dividend
- No dividends on record
- Short interest
- 2.3% of float26.9K shares · settled Sep 30, 2026 · -29.7% since Sep 15, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if NRSN is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
1 top institutions tracked
as of 2026-Q2 (filed 2026-08-14)
Insider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 1
Largest 13-F holders · Q2 2026
12 filers reported a long position in NRSN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| UBS Group AG | $78.2K | 108.6K | +121.3% |
| Independent Advisor Alliance | $72K | 100K | +100% |
| Yorkville Advisors Global, LP | $56.2K | 78K | Unchanged |
| COMMONWEALTH EQUITY SERVICES, LLC | $16.4K | 22.8K | Unchanged |
| Pathstone Holdings, LLC | $11.9K | 16.5K | Unchanged |
| GEODE CAPITAL MANAGEMENT, LLC | $11.4K | 15.9K | Unchanged |
| XTX Topco Ltd | $8.3K | 11.5K | New |
| Creative Planning | $8.2K | 11.4K | -4.2% |
| HRT FINANCIAL LP | $7K | 10.5K | New |
| JONES FINANCIAL COMPANIES LLLP | $757 | 1K | Unchanged |
Get the Full Analysis for NRSN
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.